The Food and Drug Administration on April 28 approved Takeda Pharmaceutical's lung cancer drug, Alunbrig.
Alunbrig can be used as a second-line treatment for patients with anaplastic lymphoma kinase-postive metastastic non-small cell lung cancer who are already taking Pfizer's drug crizotinib — the standard treatment for the disease.
Takeda gained rights to Alunbrig through its $5.2 billion acquisition of Ariad Pharmaceuticals in February.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps